A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment

Int J Clin Pharmacol Ther. 2011 Jan;49(1):96-8.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / analysis
  • Camptothecin / adverse effects
  • Camptothecin / analogs & derivatives
  • Camptothecin / therapeutic use
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Fluorouracil / adverse effects
  • Fluorouracil / therapeutic use
  • Humans
  • Indoles / administration & dosage
  • Indoles / pharmacokinetics
  • Indoles / therapeutic use*
  • Leucovorin / adverse effects
  • Leucovorin / therapeutic use
  • Liver Neoplasms / secondary*
  • Magnetic Resonance Imaging
  • Pyrroles / administration & dosage
  • Pyrroles / pharmacokinetics
  • Pyrroles / therapeutic use*
  • Sunitinib

Substances

  • Biomarkers, Tumor
  • Indoles
  • Pyrroles
  • Leucovorin
  • Fluorouracil
  • Sunitinib
  • Camptothecin

Supplementary concepts

  • IFL protocol